| Xembify |
125683 |
003 |
351(a) |
immune globulin subcutaneous, human-klhw |
Injection |
Subcutaneous |
2GM MG/ML |
Single-Dose Vial |
2019/07/03
|
Grifols Therapeutics LLC |
Rx |
Licensed |
|
N/A |
| Xembify |
125683 |
004 |
351(a) |
immune globulin subcutaneous, human-klhw |
Injection |
Subcutaneous |
1GM MG/ML |
Single-Dose Vial |
2019/07/03
|
Grifols Therapeutics LLC |
Rx |
Licensed |
|
N/A |
| Zirabev |
761099 |
001 |
351(k) Biosimilar |
bevacizumab-bvzr |
Injection |
Intravenous |
100MG/4ML (25MG/ML) |
Single-Dose Vial |
2019/06/27
|
Pfizer Inc. |
Rx |
Licensed |
bevacizumab |
Avastin |
| Zirabev |
761099 |
002 |
351(k) Biosimilar |
bevacizumab-bvzr |
Injection |
Intravenous |
400MG/16ML (25MG/ML) |
Single-Dose Vial |
2019/06/27
|
Pfizer Inc. |
Rx |
Licensed |
bevacizumab |
Avastin |
| Myxredlin |
208157 |
001 |
351(a) |
insulin human |
Injection |
Intravenous |
100UNITS/100ML (1UNIT/ML) |
Single-Dose Container |
2019/06/20
|
Baxter Healthcare Corporation |
Rx |
Licensed |
N/A |
N/A |
| Kanjinti |
761073 |
001 |
351(k) Biosimilar |
trastuzumab-anns |
For Injection |
Intravenous |
420MG |
Multi-Dose Vial |
2019/06/13
|
Amgen Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Polivy |
761121 |
001 |
351(a) |
polatuzumab vedotin-piiq |
For Injection |
Intravenous |
140MG |
Single-Dose Vial |
2019/06/10
|
Genentech, Inc. |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
125526 |
002 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
100MG/ML |
Autoinjector |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
125526 |
003 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
100MG/ML |
Pre-Filled Syringe |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
761122 |
001 |
351(a) |
mepolizumab |
For Injection |
Subcutaneous |
100MG |
Single-Dose Vial |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
761122 |
002 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
100MG/ML |
Autoinjector |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Nucala |
761122 |
003 |
351(a) |
mepolizumab |
Injection |
Subcutaneous |
100MG/ML |
Pre-Filled Syringe |
2019/06/06
|
GlaxoSmithKline LLC |
Rx |
Licensed |
N/A |
N/A |
| Emgality |
761063 |
003 |
351(a) |
galcanezumab-gnlm |
Injection |
Subcutaneous |
100MG/ML |
Pre-Filled Syringe |
2019/06/04
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Zolgensma |
125694 |
001 |
351(a) |
onasemnogene abeparvovec-xioi |
Injection |
Intravenous |
2x10^13VG/ML |
Single-Dose Vial |
2019/05/24
|
Novartis Gene Therapies, Inc. |
Rx |
Licensed |
|
N/A |
| Herzuma |
761091 |
002 |
351(k) Biosimilar |
trastuzumab-pkrb |
For injection |
Intravenous |
150MG |
Single-Dose Vial |
2019/05/16
|
CELLTRION, Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |
| Dengvaxia |
125682 |
001 |
351(a) |
Dengue Tetravalent Vaccine, Live |
For Injection |
Subcutaneous |
4.5-6.0 LOG10 CCID50 CCID50: CELL CULTURE INFECTIOUS DOSE 50 |
Single-Dose Vial |
2019/05/01
|
Sanofi Pasteur Inc. |
Rx |
Licensed |
|
N/A |
| Eticovo |
761066 |
001 |
351(k) Interchangeable |
etanercept-ykro |
Injection |
Subcutaneous |
50MG/ML |
Pre-Filled Syringe |
2019/04/25
|
Samsung Bioepis Co., Ltd. |
Disc |
Licensed |
etanercept |
Enbrel |
| Eticovo |
761066 |
002 |
351(k) Interchangeable |
etanercept-ykro |
Injection |
Subcutaneous |
25MG/0.5ML |
Pre-Filled Syringe |
2019/04/25
|
Samsung Bioepis Co., Ltd. |
Disc |
Licensed |
etanercept |
Enbrel |
| Skyrizi |
761105 |
001 |
351(a) |
risankizumab-rzaa |
Injection |
Subcutaneous |
75MG/0.83ML |
Pre-Filled Syringe |
2019/04/23
|
AbbVie Inc. |
Disc |
Licensed |
N/A |
N/A |
| Ogivri |
761074 |
002 |
351(k) Biosimilar |
trastuzumab-dkst |
For Injection |
Intravenous |
150MG |
Single-Dose Vial |
2019/04/17
|
Biocon Biologics Inc. |
Rx |
Licensed |
trastuzumab |
Herceptin |